Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer

Eur J Cancer. 2021 Apr:147:13-16. doi: 10.1016/j.ejca.2021.01.022. Epub 2021 Feb 16.

Authors

Leah L Thompson¹, Emily R Nadelmann¹, Amy E Blum¹, Jaewon Yoon¹, Nicole J Polyakov¹, Ruth D Kagan¹, Justin F Gainor², Meghan J Mooradian², Steven T Chen³

Affiliations

¹ Department of Dermatology, Massachusetts General Hospital & Harvard Medical School, 50 Staniford Street, Boston MA 02114, USA.
² Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, MA, USA.
³ Department of Dermatology, Massachusetts General Hospital & Harvard Medical School, 50 Staniford Street, Boston MA 02114, USA. Electronic address: stchen@partners.org.

PMID: 33607381
DOI: 10.1016/j.ejca.2021.01.022

No abstract available

Publication types

Letter

MeSH terms

Aged
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / mortality
Disease Progression
Female
Humans
Immune Checkpoint Inhibitors / adverse effects*
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / mortality
Male
Middle Aged
Progression-Free Survival
Retrospective Studies
Risk Assessment
Risk Factors
Skin / drug effects*
Skin / immunology
Skin / pathology
Skin Diseases / chemically induced*
Skin Diseases / diagnosis
Skin Diseases / immunology
Time Factors
Tumor Microenvironment

Substances

Immune Checkpoint Inhibitors